FDA Advisers Quit Over Alzheimer's Drug: 'Sham Process'

1 min read
fairly difficult
They're not happy the agency OK'd Biogen's Aduhelm against panel's recommendation
(Newser) – The week kicked off with controversy swirling around aducanumab, the drug being marketed by Biogen as Aduhelm to treat Alzheimer's disease. The drama continues, with two members of an advisory panel to the Food and Drug Administration stepping down over the agency's decision to OK the drug against the panel's recommendation. Nearly all 11 members of the committee had voted in November not to give the green light to Aduhelm as it wasn't clear it offered any real benefits to Alzheimer's patients. "I was very disappointed at how the advisory committee input…
Jenn Gidman
Read full article